Activities

MODULE DEVELOPMENT

Whilst the EORTC QLQ-C30 is an important tool for assessing the generic aspects of QOL, it has limitations and therefore a modular approach was adopted for disease-specific treatment measurements.

An essential aspect of the modular approach to QOL assessment adopted by the EORTC QLG is the development of modules specific to tumour site, treatment modality, or a QOL dimension, to be administered in addition to the core questionnaire (i.e. the EORTC QLQ-C30). The modules, like the core questionnaire, are designed for use in cancer clinical trials.

The QLG has also developed two other stand-alone questionnaires, one to assess Patient Satisfaction (EORTC IN-PATSAT32) and a short-form questionnaire for palliative care patients (EORTC QLQ-C15-PAL).

Since individual members or subgroups of the QLG are involved in module development, guidelines are needed and these have been developed to standardize the module development process. This ensures uniformly high quality across modules.

The module development process is described in detail in the "Guidelines for Developing Questionnaire Modules".

We constantly have modules in development. Information and updates can be found here.

 

TRANSLATIONS

 

All translation of the core questionnaire (EORTC QLQ-C30) and modules into other languages follows a procedure that has been described in detail in the EORTC Translation Manual (EORTC Translation Procedure, Dewolf et al., 2009).

All new modules are developed in English as well as in other European and non-European languages. The set of languages depends on the collaborators but a certain minimum number of language versions is required as per the EORTC Module Development Manual.

All translations involve two native speakers of the target language who are also fluent in the original language; they independently translate the questionnaire. The resulting translation is then "back translated" by two independent native speakers of the original language, with iterations between the forward and backward translation as necessary. There is then a pilot-test of the translated questionnaire. A formal report is submitted to the QLG, and this is reviewed by at least two members before approval is given.

The Translation Committee of the Quality of Life Group gathers at the bi-annual Group meetings to discuss methodological issues and improve the translation processes and tools.

 

FIELD STUDIES

 

The following field studies have been carried out at the EORTC Headquarters since 1986:

15861

Development of core questionnaire and lung module in lung cancer patients Publication: The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for use in international clinical trials in oncology. N.K. Aaronson et al, J. of National Cancer Institute, Vol 85, N° 5, March 1993.

15931

An international field study of the reliability and validity of the EORTC QLQ-C30 (version 3.0) and a disease-specific questionnaire module (the QLQ-BR23) in assessing the quality of life of patients with breast cancer. Study coordinator: N.K. Aaronson

15941

An international field study of the reliability and validity of the EORTC QLQ-C30 (version 3.0) and a disease-specific questionnaire module (the QLQ-H&N35) in assessing the quality of life of patients with head and neck cancer. Study coordinator: K. Bjordal

15961

An international field study of the reliability and validity of the EORTC QLQ-C30 (version 3.0) and a disease-specific questionnaire module (the QLQ-OES24) in assessing the quality of life of patients with oesophageal cancer. Study coordinator: J. Blazeby Eur. J. Cancer Jul; 39(10):1384-94; 2003.

15982

An international field study of the reliability and validity of the EORTC QLQ-C30 (version 3.0) and a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Study coordinator: A. Cull Eur. J. Cancer Jul; 39(10):1402-8; 2003.

15001

An international field study of the reliability and validity of the EORTC QLQ-C30 (version 3.0) and a disease-specific questionnaire module (the QLQ-STO22) in assessing the quality of life of patients with gastric cancer. Study coordinator: J. Blazeby Eur. J Cancer 40:2260-68; 2004.

15012

An international field study of the EORTC in Patient Satisfaction with Care measure (IN-PATSAT32). Study coordinator: A. Bredart

15011/30011

An international field study of the EORTC in patients with prostate cancer (PR25). Study coordinator: N.K. Aaronson

 

CLINICAL TRIALS

 

The fundamental structure of the EORTC is based upon disease-oriented groups which develop their clinical research through the direct input of their participating scientists. Research is accomplished mainly through the execution of large, prospective, randomized, multinational cancer clinical trials.

More than 2,000 clinicians located in 350 medical institutions in 35 countries participate in EORTC protocols. Each year thousands of patients are entered into ongoing studies.

Although there are many treatment cooperative groups in the EORTC, not all of them have included QOL as an outcome measure in their trials. However, some groups have long-standing experience in QOL assessments.

The Quality of Life Department (QLD) is involved in a wide range of studies, across most of the EORTC Cooperative Groups, through all phases, from the design, to the analysis and publication of the results.